These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16762554)

  • 1. Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors.
    Tanaka M; Sagawa S; Hoshi J; Shimoma F; Yasue K; Ubukata M; Ikemoto T; Hase Y; Takahashi M; Sasase T; Ueda N; Matsushita M; Inaba T
    Bioorg Med Chem; 2006 Sep; 14(17):5781-94. PubMed ID: 16762554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.
    Tanaka M; Sagawa S; Hoshi J; Shimoma F; Matsuda I; Sakoda K; Sasase T; Shindo M; Inaba T
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5171-4. PubMed ID: 15380221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
    Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
    Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D.
    Gamber GG; Meredith E; Zhu Q; Yan W; Rao C; Capparelli M; Burgis R; Enyedy I; Zhang JH; Soldermann N; Beattie K; Rozhitskaya O; Koch KA; Pagratis N; Hosagrahara V; Vega RB; McKinsey TA; Monovich L
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1447-51. PubMed ID: 21300545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase Cbeta protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries.
    Zhou W; Wang XL; Lamping KG; Lee HC
    J Pharmacol Exp Ther; 2006 Oct; 319(1):199-207. PubMed ID: 16861398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory action of protein kinase Cbeta inhibitor on tetrodotoxin-resistant Na+ current in small dorsal root ganglion neurons in diabetic rats.
    Hayase F; Matsuura H; Sanada M; Kitada-Hamada K; Omatsu-Kanbe M; Maeda K; Kashiwagi A; Yasuda H
    Neurosci Lett; 2007 Apr; 417(1):90-4. PubMed ID: 17339081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruboxistaurin for diabetic retinopathy.
    Gardner TW; Antonetti DA
    Ophthalmology; 2006 Dec; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
    Faul MM; Gillig JR; Jirousek MR; Ballas LM; Schotten T; Kahl A; Mohr M
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1857-9. PubMed ID: 12749884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
    Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
    J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ; Wu Y; Huang W; Zhang P; Song Y; Woolfrey J; Sinha U; Arfsten AE; Edwards ST; Hutchaleelaha A; Hollennbach SJ; Lambing JL; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1229-34. PubMed ID: 14980671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
    Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Protein Kinase C Inhibitor: Ruboxistaurin.
    Deissler HL; Lang GE
    Dev Ophthalmol; 2016; 55():295-301. PubMed ID: 26501476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
    Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.